Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery

This is an interventional treatment trial for Cervical Cancer focused on measuring recurrent ovarian epithelial cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, recurrent ovarian germ cell tumor, stage III ovarian germ cell tumor, stage IV ovarian germ cell tumor, recurrent endometrial carcinoma, stage III endometrial carcinoma, stage IV endometrial carcinoma, recurrent uterine sarcoma, stage III uterine sarcoma, stage IV uterine sarcoma, recurrent vaginal cancer, stage III vaginal cancer, stage IVA vaginal cancer, stage IVB vaginal cancer, recurrent vulvar cancer, stage III vulvar cancer, stage IV vulvar cancer, recurrent cervical cancer, stage III cervical cancer, stage IVA cervical cancer, stage IVB cervical cancer, fallopian tube cancer, ovarian sarcoma, ovarian stromal cancer Read More

DISEASE CHARACTERISTICS:

• Histologically* or cytologically confirmed unresectable gynecologic malignancy for which standard curative or palliative care is not available

  • All tumor types allowed NOTE: *Histologic confirmation of recurrence is not required

• Measurable or nonmeasurable disease

  • If CT scan was used to evaluate measurable disease, lesions must be clearly defined and be ≥ 10 mm on spiral CT scan
• No "borderline tumors" or tumors with low malignant potential

PATIENT CHARACTERISTICS:

• Karnofsky performance status 60-100%
• Life expectancy ≥ 12 weeks
• ANC ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Hemoglobin ≥ 9 g/dL
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Creatinine clearance ≥ 60 mL/min
• AST/ALT ≤ 2.5 times ULN (< 5 times ULN if liver metastases are present)
• Alkaline phosphatase ≤ 2.5 times ULN (< 5 times ULN if liver metastases are present)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Adequate intestinal function (i.e., no gastrostomy tube or requirement for IV hydration or nutritional support)
• No severe gastrointestinal bleeding or intestinal obstruction
• No other condition that would affect gastrointestinal absorption and motility
• No septicemia, severe infection, or acute hepatitis
• No other malignancies requiring chemotherapy or radiotherapy within the past 5 years, except skin cancer
• No concurrent severe medical problem unrelated to the malignancy that would significantly limit full compliance with the study, expose the patient to extreme risk, or decrease life expectancy

PRIOR CONCURRENT THERAPY:

• At least 28 days since prior investigational drugs (including cytotoxic drugs)
• At least 4 weeks since prior chemotherapy, radiotherapy, biologic therapy, or surgery and recovered
• No more than 3 prior chemotherapy regimens
• No prior topotecan hydrochloride or other camptothecin analogs
• No prior radiotherapy to > 25% of the bone marrow
• No other concurrent chemotherapy, radiotherapy, biologic therapy, immunotherapy, or hormonal therapy for cancer

• No concurrent administration of any of the following:

  • P-glycoprotein (ABCB1, Pgp, MDR1) inhibitors or inducers
  • Breast cancer-resistant protein (ABCG2, BCRP, MXR) inhibitors or inducers

• No concurrent chronic H2 antagonists, proton pump inhibitors, or antacids for gastritis, gastroesophageal reflux disease, or gastric or duodenal ulcers

  • Intermittent antacid therapy is allowed provided it is given ≥ 6 hours prior to and ≥ 90 minutes after study drug administration